Li Watsek
Stock Analyst at Cantor Fitzgerald
(1.31)
# 3,444
Out of 4,876 analysts
76
Total ratings
41.77%
Success rate
-19.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KURA Kura Oncology | Reiterates: Overweight | n/a | $5.74 | - | 11 | Jun 26, 2025 | |
| REPL Replimune Group | Initiates: Overweight | n/a | $9.47 | - | 1 | Jun 20, 2025 | |
| ASND Ascendis Pharma | Reiterates: Overweight | $200 | $173.00 | +15.61% | 18 | May 12, 2025 | |
| ZLAB Zai Lab | Reiterates: Overweight | n/a | $34.66 | - | 1 | Mar 27, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.29 | - | 2 | Mar 26, 2025 | |
| TARA Protara Therapeutics | Initiates: Overweight | n/a | $3.00 | - | 1 | Mar 14, 2025 | |
| ARVN Arvinas | Reiterates: Overweight | n/a | $7.76 | - | 5 | Feb 7, 2025 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $0.46 | - | 7 | Jan 24, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $22.08 | - | 2 | Jan 13, 2025 | |
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $8.43 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $4.77 | +319.29% | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.30 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.11 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.18 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.93 | +55.44% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $220 | $5.87 | +3,647.87% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.07 | +367.29% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $1.73 | +2,096.53% | 1 | Aug 12, 2022 |
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.74
Upside: -
Replimune Group
Jun 20, 2025
Initiates: Overweight
Price Target: n/a
Current: $9.47
Upside: -
Ascendis Pharma
May 12, 2025
Reiterates: Overweight
Price Target: $200
Current: $173.00
Upside: +15.61%
Zai Lab
Mar 27, 2025
Reiterates: Overweight
Price Target: n/a
Current: $34.66
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.29
Upside: -
Protara Therapeutics
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.00
Upside: -
Arvinas
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $7.76
Upside: -
ALX Oncology Holdings
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $0.46
Upside: -
IDEAYA Biosciences
Jan 13, 2025
Reiterates: Overweight
Price Target: n/a
Current: $22.08
Upside: -
Arcus Biosciences
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.43
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $20
Current: $4.77
Upside: +319.29%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.30
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.11
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.18
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.93
Upside: +55.44%
Sep 7, 2023
Reiterates: Overweight
Price Target: $220
Current: $5.87
Upside: +3,647.87%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.07
Upside: +367.29%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $1.73
Upside: +2,096.53%